Loading…

Loading grant details…

Active NON-SBIR/STTR RPGS NIH (US)

Assessment of strategies for targeting transcriptional co-activators in colorectal cancer

$4.39M USD

Funder NATIONAL CANCER INSTITUTE
Recipient Organization University of Nebraska Medical Center
Country United States
Start Date Aug 15, 2024
End Date Jul 31, 2029
Duration 1,811 days
Number of Grantees 1
Roles Principal Investigator
Data Source NIH (US)
Grant ID 10943743
Grant Description

Project Summary: PGC-1 family proteins (PGC-1α, PGC-1β, and PPRC1) are transcriptional coactivators that act as central hubs to coordinate diverse cellular inputs to promote the transcription of genes that regulate metabolism to maintain homeostasis. Transcriptional coactivator Peroxisome Proliferator-Activated Receptor Gamma

Coactivator 1 β (PGC-1β) is over-expressed in colorectal cancers (CRC) with K-Ras mutations and promotes the survival of tumor cells. PGC-1 family proteins lack intrinsic enzymatic activity and function by facilitating interactions between transcription factors, epigenetic modifiers, and transcription initiation machinery. To identify

the protein-protein interactions required by PGC-1β to promote gene expression we immunoprecipitated PGC- 1β and identified binding partners by mass spectrometry. Our data reveal that Estrogen-Related Receptor α (ERRα) and Host Cell Factor 2 (HCF2) are PGC-1β binding proteins that we propose are required for PGC-1β

to regulate the transcription of genes that promote CRC survival. Our long-term goal is to inhibit CRC growth by blocking PGC-1β signaling and we propose that can be achieved by preventing PGC-1β from signaling through either ERRα or HCF2. In Aim 1, we will determine the mechanism by which phosphatase PGAM5

modifies PGC-1β to increase ERRα transcription. In Aim 2, we will identify PGC-1β-HCF2 regulated genes and determine the requirements for HCF2 signaling. In Aim 3, we will test the loss of the PGC-1β, the loss of the PGC-1β-ERRα interaction, the loss of the PGC-1β-HCF2 interaction, and the loss of both interactions in vivo

using orthotopic submucosal injections in immunodeficient mice receiving Crispr-Cas9-modified patient-derived tumor organoids establish from liver metastases.

All Grantees

University of Nebraska Medical Center

Advertisement
Discover thousands of grant opportunities
Advertisement
Browse Grants on GrantFunds
Interested in applying for this grant?

Complete our application form to express your interest and we'll guide you through the process.

Apply for This Grant